vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Walker & Dunlop, Inc. (WD). Click either name above to swap in a different company.
Walker & Dunlop, Inc. is the larger business by last-quarter revenue ($340.0M vs $191.2M, roughly 1.8× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs -0.4%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 22.1%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Walker & Dunlop, Inc. is one of the largest commercial real estate finance and advisory services firms in the United States and internationally.
AXSM vs WD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $340.0M |
| Net Profit | — | $-13.9M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | -17.2% |
| Net Margin | — | -12.9% |
| Revenue YoY | 57.4% | -0.4% |
| Net Profit YoY | — | -131.0% |
| EPS (diluted) | — | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $340.0M | ||
| Q3 25 | $171.0M | $337.7M | ||
| Q2 25 | $150.0M | $319.2M | ||
| Q1 25 | $121.5M | $237.4M | ||
| Q4 24 | $118.8M | $341.5M | ||
| Q3 24 | $104.8M | $292.3M | ||
| Q2 24 | $87.2M | $270.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $-13.9M | ||
| Q3 25 | $-47.2M | $33.5M | ||
| Q2 25 | $-48.0M | $34.0M | ||
| Q1 25 | $-59.4M | $2.8M | ||
| Q4 24 | $-74.9M | $44.8M | ||
| Q3 24 | $-64.6M | $28.8M | ||
| Q2 24 | $-79.3M | $22.7M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | -17.2% | ||
| Q3 25 | -27.0% | 13.6% | ||
| Q2 25 | -24.5% | 14.5% | ||
| Q1 25 | -46.9% | 2.2% | ||
| Q4 24 | -61.1% | 15.3% | ||
| Q3 24 | -59.8% | 12.8% | ||
| Q2 24 | -89.5% | 10.4% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | -12.9% | ||
| Q3 25 | -27.6% | 9.9% | ||
| Q2 25 | -32.0% | 10.6% | ||
| Q1 25 | -48.9% | 1.2% | ||
| Q4 24 | -63.1% | 13.1% | ||
| Q3 24 | -61.7% | 9.9% | ||
| Q2 24 | -91.0% | 8.4% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $-0.41 | ||
| Q3 25 | $-0.94 | $0.98 | ||
| Q2 25 | $-0.97 | $0.99 | ||
| Q1 25 | $-1.22 | $0.08 | ||
| Q4 24 | $-1.54 | $1.32 | ||
| Q3 24 | $-1.34 | $0.85 | ||
| Q2 24 | $-1.67 | $0.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $299.3M |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $1.7B |
| Total Assets | $713.6M | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $299.3M | ||
| Q3 25 | $325.3M | $274.8M | ||
| Q2 25 | $303.0M | $233.7M | ||
| Q1 25 | $300.9M | $181.0M | ||
| Q4 24 | $315.4M | $279.3M | ||
| Q3 24 | $327.3M | $179.8M | ||
| Q2 24 | $315.7M | $208.1M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $1.7B | ||
| Q3 25 | $73.7M | $1.8B | ||
| Q2 25 | $73.1M | $1.8B | ||
| Q1 25 | $53.2M | $1.7B | ||
| Q4 24 | $57.0M | $1.7B | ||
| Q3 24 | $92.9M | $1.7B | ||
| Q2 24 | $102.9M | $1.7B |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $5.1B | ||
| Q3 25 | $669.3M | $5.8B | ||
| Q2 25 | $639.8M | $4.7B | ||
| Q1 25 | $596.7M | $4.5B | ||
| Q4 24 | $568.5M | $4.4B | ||
| Q3 24 | $561.5M | $4.6B | ||
| Q2 24 | $548.2M | $4.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-664.3M |
| Free Cash FlowOCF − Capex | — | $-680.1M |
| FCF MarginFCF / Revenue | — | -200.0% |
| Capex IntensityCapex / Revenue | — | 4.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.2B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-664.3M | ||
| Q3 25 | $1.0M | $-948.1M | ||
| Q2 25 | $-32.4M | $-238.5M | ||
| Q1 25 | $-43.4M | $-281.1M | ||
| Q4 24 | $-26.2M | $129.4M | ||
| Q3 24 | $-18.6M | $-202.0M | ||
| Q2 24 | $-30.1M | $-237.8M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-680.1M | ||
| Q3 25 | $988.0K | $-950.4M | ||
| Q2 25 | $-32.4M | $-241.0M | ||
| Q1 25 | $-43.7M | $-284.7M | ||
| Q4 24 | $-26.2M | $116.4M | ||
| Q3 24 | $-18.7M | $-204.0M | ||
| Q2 24 | $-30.2M | $-241.7M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | -200.0% | ||
| Q3 25 | 0.6% | -281.5% | ||
| Q2 25 | -21.6% | -75.5% | ||
| Q1 25 | -36.0% | -120.0% | ||
| Q4 24 | -22.1% | 34.1% | ||
| Q3 24 | -17.9% | -69.8% | ||
| Q2 24 | -34.6% | -89.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 4.6% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.3% | 1.5% | ||
| Q4 24 | 0.0% | 3.8% | ||
| Q3 24 | 0.1% | 0.7% | ||
| Q2 24 | 0.1% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -28.34× | ||
| Q2 25 | — | -7.02× | ||
| Q1 25 | — | -102.07× | ||
| Q4 24 | — | 2.89× | ||
| Q3 24 | — | -7.01× | ||
| Q2 24 | — | -10.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
WD
Segment breakdown not available.
